Related Experiment Video
Updated: May 18, 2026

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
A20 (TNFAIP3) alleviates CVB3-induced myocarditis via inhibiting NF-κB signaling
Jun Gui1, Yan Yue, Ruizhen Chen
1Institute for Immunobiology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Insights
A20 protein protects against Coxsackievirus B3-induced myocarditis by reducing inflammation and inhibiting the NF-κB signaling pathway. This finding offers a potential new therapeutic strategy for viral myocarditis treatment.
Area of Science:
- Cardiology
- Virology
- Immunology
Background:
- Viral myocarditis, often caused by Coxsackievirus B3 (CVB3), involves cardiac inflammation.
- Current therapies for inflammation in viral myocarditis are insufficient.
- A20 (TNFAIP3) is a known negative regulator of inflammation, but its role in CVB3-induced myocarditis was unclear.
Purpose of the Study:
- To investigate the protective effects of A20 against CVB3-induced myocarditis.
- To elucidate the molecular mechanisms underlying A20's potential role.
Main Methods:
- Established a mouse model of acute viral myocarditis via CVB3 inoculation.
- Administered adenovirus expressing A20 (Ad-A20) intravenously.
- Measured pro-inflammatory cytokine levels (TNF-α, IL-1β, IL-6, MCP-1).
- Assessed the activity of the NF-κB signaling pathway and TRAF6 ubiquitylation.
Main Results:
- CVB3 infection markedly increased pro-inflammatory cytokines, correlating with disease severity.
- Ad-A20 treatment significantly reduced these cytokines and alleviated myocarditis severity.
- A20 inhibited CVB3-induced NF-κB signaling.
- A20 restricted TRAF6 ubiquitylation, thereby inhibiting NF-κB signaling.
Conclusions:
- A20 demonstrates a protective role against CVB3-induced myocarditis.
- A20 functions by inhibiting the NF-κB signaling pathway.
- A20 represents a potential novel therapeutic strategy for viral myocarditis.
Background:
Viral myocarditis, which is most prevalently caused by Coxsackievirus B3 (CVB3) infection, is a serious clinical condition characterized by cardiac inflammation. However, efficient therapies targeting inflammation are still lacking and much needed. A20, also known as tumor necrosis factor alpha induced protein 3 (TNFAIP3) is a key negative regulator of inflammation. But whether A20 may affect cardiac inflammation during acute viral myocarditis remains to be elucidated. The aim of this study was to investigate the potential protective effect of A20 on CVB3-induced myocarditis.
Methodology/Principal Findings:
Mice were intraperitoneally inoculated with CVB3 to establish acute viral myocarditis model. We found that the expression of pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6 and monocyte chemotactic protein-1 (MCP-1) were markedly and persistently increased during the progression of CVB3-induced myocarditis, and positively correlated with the disease severity. Notably, intravenous injection in vivo with adenovirus expressed A20 (Ad-A20) remarkably reduced CVB3-induced pro-inflammatory cytokines production and alleviated the severity of myocarditis. Further, we observed that nuclear factor-kappaB (NF-κB) signaling which mediates inflammatory response was significantly inhibited in CVB3-infected mice with Ad-A20 treatment. Finally, we revealed that A20 was required to inhibit CVB3-induced NF-κB signaling by restricting TNF receptor associated factor 6 (TRAF6) ubiquitylation.
Conclusion/Significance:
This study demonstrates the protective role of A20 against CVB3-induced myocarditis, which may provide a new therapeutic strategy for the treatment of viral myocarditis.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-kB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Myocarditis III: Medical Management
TGF - β Signaling Pathway
Myocarditis I: Introduction
Myocarditis IV: Nursing Management